ATC Group: N07AA03 Distigmine

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of N07AA03 in the ATC hierarchy

Level Code Title
1 N Nervous system
2 N07 Other nervous system drugs
3 N07A Parasympathomimetics
4 N07AA Anticholinesterases
5 N07AA03 Distigmine

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
ORAL - Oral 5 mg
PAREN - Parenteral 0.25 mg

Active ingredients in N07AA03

Active Ingredient Description
Distigmine

Related product monographs

Title Information Source Document Type  
UBRETID Tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC

Medicines in this ATC group

Austria (AT)

Estonia (EE)

Hong Kong (HK)

Japan (JP)

Netherlands (NL)

Poland (PL)

Singapore (SG)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.